


Advancing Transfusion and Cellular Therapies Worldwide


Highlights


200 hospitals from 43 states completed the 2021 AABB COVID-19 hospital transfusion services survey , conducted from Jan. 4-Jan. 11, 2021.

- Most of the hospitals reported transfusing CCP in the range of 0-24 units.
- 26.0% of the hospitals reported increasing, 28.0% reported about the same and 34.0% reported a declining trend of CCP transfusion.
- 28.7% reported delays in obtaining CCP units, an upward trend since the week of Oct. 26 survey. Delays in Group AB and B CCP units are most reported.
- Based on the responses to this survey, the average CCP dose to patient ratio among the AABB member hospitals is estimated to be 1.3:1. Since a majority of the hospitals reported the use of CCP was at the discretion of the individual ordering physician/team, variability in the estimate can be expected in studies conducted at a different time and with a different survey population.

2021 AABB COVID-19 Hospital Transfusion Services Survey Final Report









Data: AABB Hospital survey


srajbhandary@aabb.org

©AABB 2021


2021 AABB COVID-19 Hospital Transfusion Services Survey Final Report














Data : AABB Hospital survey srajbhandary@aabb.org




2021 AABB COVID-19 Hospital Transfusion Services Survey Final **Report**












2021 AABB COVID-19 Hospital Transfusion Services Survey Final Report



28.7% of the hospitals responding the question above (n=188) reported delays in obtaining CCP units. Most hospitals specified delay was associated only with Group AB and B CCP units. States with highest number of hospitals reporting delay were North Carolina (7), Pennsylvania (6) and Michigan (4).